Gyurdieva, Alexandra
Zajic, Stefan
Chang, Ya-Fang
Houseman, E. Andres
Zhong, Shan http://orcid.org/0000-0001-5871-3634
Kim, Jaegil
Nathenson, Michael
Faitg, Thomas
Woessner, Mary
Turner, David C.
Hasan, Aisha N.
Glod, John
Kaplan, Rosandra N. http://orcid.org/0000-0002-8580-0001
D’Angelo, Sandra P. http://orcid.org/0000-0002-3736-3783
Araujo, Dejka M.
Chow, Warren A.
Druta, Mihaela
Demetri, George D.
Van Tine, Brian A. http://orcid.org/0000-0003-4572-6668
Grupp, Stephan A. http://orcid.org/0000-0001-8030-7595
Fine, Gregg D.
Eleftheriadou, Ioanna http://orcid.org/0000-0002-0278-1061
Funding for this research was provided by:
GlaxoSmithKline
Article History
Received: 10 August 2021
Accepted: 1 August 2022
First Online: 8 September 2022
Competing interests
: A.G. is an employee of and holds stocks/shares in GSK and holds stocks/shares in Amgen. St.Z., E.A.H., J.K., M.N., T.F., M.W., D.C.T. and I.E. are employees of and hold stocks/shares in GSK. Y.F.C. is an employee of GSK. Sh.Z. is a former employee of and holds stocks/shares in GS.K. A.N.H. is a former employee of and holds stocks/shares in GSK and receives patents and royalties from Atara Biotherapeutics. J.G. is protocol investigator for SARC and PBTC sponsored studies. R.N.K. and D.M.A. have no disclosures. S.P.D.A. participated on advisory boards for GSK, Nektar, Adaptimmune, and Merck; reports consulting fees from EMD Serono, Amgen, Nektar, Immune design, GSK, Incyte, Merck, Adaptimmune, and Immunocore, and received support for travel expense by Adaptimmune, EMD Serono, and Nektar. WAC reports grant and honoraria received from GSK. M.D. has received consulting fees from Adaptimmune and honoraria from Deciphera. GDD reports leadership roles with Blueprint Medicines, Merrimack Pharmaceuticals (ended Oct 2019), and Translate Bio (ended Sept 2021); stocks/options/shares in Blueprint Medicines, G1 Therapeutics, Caris Life Sciences, Erasca Pharmaceuticals, RELAY Therapeutics, Bessor Pharmaceuticals, CellCarta, IKENA Oncology, Kojin Therapeutics, and IDRX; paid consulting fees from Bayer, Pfizer, Novartis, Roche/Genentech, GSK, PharmaMar, Daiichi Sankyo, GSK, EMD-Serono, MEDSCAPE, Mirati, WCG/Arsenal Capital, MJ Hennessey/OncLive, C4 Therapeutics, Synlogic, McCann Health, G1 Therapeutics, Caris Life Sciences, RELAY Therapeutics, CellCarta, IKENA Oncology, Kojin Therapeutics and IDRX; royalties, patents or licenses from Novartis via Dana Farber for “use patent” of imatinib in GIST; and non-financial interests in AACR Science Policy and Government Affairs Committee and Alexandria Real Estate Equities summit conference series. BAVT received consulting fees from ADRx, Ayala Pharmaceuticals, Cytokinetics Inc, and Bayer; has honoraria from Adaptimmune Ltd, GSK, Bionest Partiners, and Intellisphere LLC; has received payment for expert testimony from Hinshaw & Culbertson LLP, Rodney Law, CRICO Risk Management Foundation, and Tracey & Fox Law Firm; has received research funding from GSK, Merck, Pfizer, and Tracon; has received travel, accommodations, and expenses from GSK and Adaptimmune; has participated on advisory board meeting with Adaptimmune Ltd, Apexigen Inc, Boehringer Ingelheim, Daiichi Sankyo, Deciphera Pharmaceuticals Inc, Epizyme, GSK, Novartis, PTC Therapeutics, and Lilly, and is a board member for Polaris; and holds royalties or licenses for work performed with Accuronix Therapeutics. S.A.G. has received grants for study support from Novartis, Jazz Pharmaceuticals, Kite, Vertex, and Servier; has received consulting fees from Novartis, Roche, GSK, Vertex/CRISPR, CBMG, and Janssen/JnJ; has received payment for expert testimony from Irwin Mitchell and Jones Day; has patents managed according to the University of Pennsylvania patent policy; has participated on advisory boards for Novartis, Jazz Pharmaceuticals, Adaptimmune, Cellectis, Juno, Vertex, Allogene, and Cabaletta. G.D.F. is a former employee of GSK and has stock options in GSK and PACT Pharma, and holds stocks in Bluebird Bio, Agios, and BioMarin.